



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q61434

Toshikazu NAKAMURA

Appln. No.: 09/674,377

Group Art Unit: 1647

Confirmation No.: 7003

Examiner: Lorraine Spector

Filed: October 30, 2000

For: NEOVASCULARIZATION INHIBITORS DERIVED FROM HGF AND METHODS INVOLVING THE SAME (as amended)

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

MAIL STOP SEQUENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In connection with the Substitute Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. §1.821(g), does not include any new matter;
2. the content of the 5 pages Sequence Listing being filed herewith, and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are identical; and
3. all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by .

Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821-1.825
U.S. Appln. No. 09/674,377
SUGHRUE MION, PLLC Attorney docket: Q61434

fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that
such willful false statements may jeopardize the validity of the application or any patent resulting
therefrom.

Respectfully submitted,


Mark L. Hayman
Registration no. 51,793

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 18, 2006